Matrix compares old vs new EU GMP Guide Part I, Chapter 8 - effective as of 1 March 2015
Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
Register now for ECA's GMP Newsletter
Starting with the 1 March 2015 the revised EU GMP Guide Part I, Chapter 8 (Complaints, Quality Defects and Product Recall) becomes effective (see also our GMP News from 23 September 2014). Until then the version with the validity date 1 February 2006 is still applicable.
The following matrix provides you with a compact overview of the changes. It allows you to quickly compare it with an existing QM system and can thus be used for a "GAP" analysis, a self inspection or for audits.
| EU GMP Guide Part I, Chapter 8 Version effective as of 1 March 2015 (new version) | EU GMP Guide Part I, Chapter 8 Version effective until 28 Feb. 2015 (old version) |
| Principles (supplemented by: - QRM requirements - Reference to chapter 1 - Reference to competent authority - Reference to chapter 7) | Principles |
| Personnel and Organisation | - |
| 8.1 (supplemented by: - Independence of Marketing and sales - Emphasizing Training) | 8.1 |
| 8.2 | - |
| 8.3 | - |
| 8.4 | - |
| Procedures for handling investigations of complaints including quality defects | Complaints |
| 8.5 | 8.2 (partly) |
| 8.6 (supplemented by: - Special focus on falsification) | 8.7 |
| 8.7 | - |
| 8.8 | Comparable to 8.4 |
| 8.9 (supplemented by: - Investigation procedures described in detail, e.g. CAPA) | Comparable to 8.2 |
| Investigation and decision making | - |
| 8.10 (supplemented by: - QRM requirements - QC not mentioned any longer) | 8.3/8.5 |
| 8.11 (Rework not mentioned any longer) | 8.4 |
| 8.12 | Comparable to 8.6 |
| 8.13 | - |
| 8.14 (supplemented by: - Early phases of investigation - Decision making process - Risk reducing actions) | Partly 8.5 |
| 8.15 (Counterfeits not mentioned) | 8.7 |
| Root Cause analysis and CAPA | - |
| 8.16 | - |
| 8.17 | - |
| 8.18 (supplemented by - CAPA and effectiveness monitoring and assesment) | Comparable to 8.6 |
| 8.19 (supplemented by: - Trending) | Comparable to 8.6 |
| Product recalls and other potential risk reducing measures | Recalls |
| 8.20 (supplemented by: - Risk reducing actions) | 8.10 |
| 8.21 | - |
| 8.22 (supplemented by: - Recalls prior to a root cause analysis) | 8.11 |
| 8.23 | 8.13 |
| 8.24 | - |
| 8.25 (supplemented by: - Scope of recall regarding the distribution network - Missing recall due to short shelf-life products) | 8.12 |
| 8.26 (supplemented by: - Need for recall prior to information of authority - Cooperation with competent authority) | 8.12 |
| 8.27 | - |
| 8.28 (supplemented by: - Details regarding Rework) | 8.14 |
| 8.29 | 8.15 |
| 8.30 (supplemented by: - Mock recall) | 8.16 |
| 8.31 | - |
QRM: Quality Risk Management, QC: Quality Control, CAPA Corrective And Preventive Action
Related GMP News
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years